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ABSTRACT 
Objectives: In this study it is proposed to analyse the effect of bariatric metabolic surgery on diabetes remission in obese type 2 diabetic patients 
compared to conventionally treated similar patients. 
Methods: A retrospective review, of prospectively collected data base of conventionally treated group and metabolic group were screened from the 
year 2010-2013 at the study centre for patients satisfying the inclusion criteria. Three follow up data at an interval of three months and a base line 
value for both group were collected. Primary outcome measures the percentage of patient achieved diabetes remission, i.e. glycosylated 
haemoglobin (HbA1c)<6 % without active pharmacological therapy at one year and percentage of patients who achieved excess weight loss more 
than 60 % at one year. 
Secondary outcome includes percentage reduction in medication use. Statistics used in the study is student‘t’ test, Chi-square and ANOA (Analysis of 
Variance). The treatment effects were found to be significant to the least significant difference (LSD) at 5% level of significance. 
Results: The patients underwent bariatric surgery had a significant improvement in glycemic status (HbA1c<6 %). In conventionally treated group 
less than 5% achieved HbA1c less than 6.5 % level with active pharmacological therapy. There was an increased use of antidiabetic medication with 
2-5% increase in mean body weight in conventional group. 
Conclusion: Compared to conventional therapy bariatric surgery markedly improves diabetes and results in discontinuation or marked reduction 
of anti-diabetic medications in majority of patients treated. So bariatric surgery seems to be a better option for the obese diabetic patients. 
Keywords: Bariatric metabolic surgery, Glycosylated hemoglobin, Obesity, Type 2 diabetes, Body Mass Index, Weight loss. 
 
INTRODUCTION 
The growing incidence of obesity and type 2 diabetes is one of the 
most challenging contemporary threats to the public health as 
changing lifestyle leads to reduced physical activity and increased 
obesity. The rise in the prevalence of obesity is associated with the 
increase in type 2 diabetes mellitus (DM), hyperlipidemia, 
hypertension, obstructive sleep apnoea, heart disease, polycystic 
ovary, stroke, asthma, several forms of cancer and depression [1]. 
The initial treatment for type 2DM associated with obesity is 
lifestyle modification involving dietary modification and increased 
physical activity with or without active pharmacological therapy [2]. 
To maintain glycemic status and average weight loss for a long 
period of time with lifestyle intervention alone is difficult to achieve. 
Except metformin most glucose lowering drugs causes weight gain 
[3]. The introduction of glucagon-like peptide-1(GLP-1), dipeptidyl 
peptidase inhibitors and sodium dependent glucose transporter-2 
inhibitors has altered the management of type 2DM because these 
agents do not cause weight gain [4, 5].  
However there are limited data on the long term efficacy of these 
drugs. Both consensus meeting and international Diabetes 
federation have recommended consideration of bariatric surgery for 
control of type 2DM when obesity is severe and/or available medical 
therapies fail to control diabetes Evidences from different studies 
suggest that bariatric surgery can improve type 2 diabetes [6]. A 
high profile Meta analysis by Buchwald et al. reported that 78% 
resolution in type 2DM following bariatric surgery [7]. This study 
changed clinician’s focus of bariatric surgery for weight loss to cure 
of diabetes gave rise to the term “metabolic surgery”[8]. 
Present study was done with an objective to investigate the impact 
of bariatric metabolic surgery on excess weight loss and diabetes 
remission at one year of treatment in obese type 2 diabetes patients 
compared to a conventionally treated matched patient group. 
MATERIALS AND METHODS 
This retrospective observational study was conducted at the 
bariatric and metabolic surgery department of Moulana hospital 
after receiving the institutional ethical committee approval. The 
study population who had undergone medical treatment and 
metabolic surgery for diabetes were retrospectively identified 
from the medical records of the hospital. Medical records between 
the years 2010 January to 2013 December were screened for 
selection of patients. Patients satisfying the criteria, age between 
25–60 years, BMI>32.5 kg/m2
The patients of both groups were matched for age, gender, BMI 
and glycosylated haemoglobin. Diagnosis of type 2DM was made 
according to American Diabetes Association guidelines and 
surgery followed fulfilment of the Consensus in Asia–Pacific2005 
criteria [6, 9]. The initial data collected at base line includes 
height, weight, HbA1c, co–morbidities, and medications for both 
groups. Similarly follow-up data were collected at three months 
interval which includes change in BMI, weight loss, HbA1c, and 
medication use pattern. BMI is calculated using the formula 
weight in kilogram divided by height in meter square. Weight 
loss is reported as the mean percentage of excess weight loss 
which is the standard in bariatric procedures. The formula used 
for finding percentage excess weight loss is equal to weight loss 
divided by excess weight multiplied by 100. Ideal body weight is 
calculated from the standard table which has ideal weight 
corresponding to each BMI. 
 with type 2DM for more than 2 
years and HbA1c not less than 7.5% at base level with a minimum 
follow up of 18 months were selected for the study. A total of 150 
patients of which 85 females and 65 males who met the inclusion 
criteria were selected for metabolic surgery group and in the 
conventional group there was 155 patients of which 70 females 
and 85 males.  
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Outcome measure 
Primary outcome was the percentage of patients achieved diabetes 
remission (HbA1c<6 % without active pharmacological therapy) and 
percentage of patients who lost>60% excess body weight. Secondary 
outcome includes percentage reduction of medication use in both 
groups.  
Statistics  
Statistical analysis was done using independent‘t’ test for 
comparison of means chi-square for goodness of fit of ratios and 2 
factor ANOVA for comparison of parameters between groups. 
RESULTS AND DISCUSSION 
Table1 gives the mean, standard deviation (SD) and the‘t’ values of 
the baseline data for conventional and surgical groups. There is no 
significant difference in glycemic status and gender between groups, 
but the mean age, duration of diabetes and BMI between groups 
differ significantly. The mean age of conventional group was 
47.5±9.15 and bariatric group it was 41.47±7.72, duration of 
diabetes in conventional group 11.65±6.75 and in bariatric group it 
was 7.67±5.24, BMI in conventional group was 37.24±6.18, 
bariatric group 42.13±7.24 and in conventional group excess mean 
% weight was 20.06±13.89, in bariatric group 63.60±23.85. From 
the table it is clear that obesity is dominant among people in the age 
group between 36 to 45years. Similar report was published by Unni 
et al. [10]. 
BMI and excess weight loss% 
Tables 2 and 3 give a comparison of means of BMI, excess weight 
loss%, Glycosylated haemoglobin, and insulin units per day and oral 
hypoglycemic agents (OHA) in the three follow ups of the 
conventional and bariatric groups. The bariatric surgery produced 
significant and desirable excess weight loss%. At baseline, patients 
in the bariatric group weighed more BMI average (42.13±7.24) 
compared to conventional group BMI 37.±6.18. At the end of the 
study period there was an increase in mean BMI from 37.24±6.18 
to37.45±4.56 in the conventional group. The second parameter 
excess weight loss showed a sharp reduction in bariatric group 
whereas it showed no reduction in conventional group. Weight loss 
is the most important parameter of bariatric surgery. The fig. 1 
shows the graphical representation of excess weight loss% in 
bariatric group. Here the average weight loss per follow up 
was>20% and excess weight loss at the end of the study was>60%. 
In our study more than sixty percent patients lost their excess body 
weight by 60%. More than 50% excess weight loss indicates success 
of bariatric surgery [8]. Retrospectively reviewed 102 patients and a 
similar result were published. 
 
Table1: Preoperative parameters of study population 
Parameter Conventional group Bariatric group Significance 
 n mean SD n mean SD t df p-value 
Age 155 47.5 9.15 150 41.47 7.72 13.458 303 P<0.01 
DM duration 155 11.65 6.75 150 7.67 5.24 5.762 303 ***P<0.001 
BMI 155 37.24 6.18 150 42.13 7.24 16.448 303 P<0.01 
Excess % wt  155 20.06 13.89 150 63.60 23.85 16.504 303 P<.001 
Glycosylated haemoglobin 155 8.01 1.23 150 7.9 1.80 8.277 303 NS 
Insulin  130 51 6.24 78 49.5 7.71 8.697 183 P<0.05 
Metformin+combination 25 1533.33 561.74 72 1071.43 305.12 7.340 188 P<0.001 
*pvalue<0.05 p **<0.01,***p value<0.001 df (degree of freedom),NS-not significant, *pvalue<0.05(significant) p**<0.01, (more significant) ***p 
value<0.001 (highly significant) 
 
Table 2: Follow up parameters in conventional group (CG) 
parameters No of patients First follow up  Second follow up  Third follow up P value 
BMI (mean±SD) 155 37.37±4.68 37.33±4.08 37.45±4.56 NS 
Excess weight loss%  155 nil nil nil NS 
Glycosylated haemoglobin 155 8.01±0.78 7.9±0.75 7.5±08 NS 
Insulin+OHA units/day 130 44±6.24 40±21 45±26 
N=135 
>0.05 
OHA alone(mg) 25 1554±250 1255±365 1583±345 
N=20 
>0.05 
OHA-Oral hypoglycaemic agents, BMI-Body Mass Index 
 
Table 3: Follow up parameters in bariatric group (BG) 
Parameters No of patients First follow up  Second follow up  Third follow up P value 
BMI (mean±SD) 150 38.30±7.9 35.05±6.83 32.26±4 <.001 
Exces weight loss%  150 15.69±9.62 26.79±9 20.83±11 <0.001 
Glycosylated hemoglobin 150 6.9±0.56 6.33±0.25 5.88±0.25 <.01 
Insulin units 78 33±6.24 32 (N=10) 00 (N=0) >0.001 





*p value<.05 (significant) p **<.01 (more significant) ***p value.001 (highly significant), CG (Conventional group), BG (Surgical Group) 
 
Diabetes remission and use of anti diabetic medication 
At base line, 86% of conventional group was receiving insulin at an 
average of 44±6.24 units. This was increased to 87% and dose also 
increased to 45±26 units at the end of the study. Remaining 13% 
were on oral hypoglycaemic drug metformin alone or in 
combination at an average dose of 1533.33±561.74. In bariatric 
group 52% were using insulin at an average 49.5±7.71 U and 48% 
were on OHA in double and triple drug combinations at an average 
dose of 1071.43±305.12 mg/day. Months after surgery, the insulin 
intake was drastically reduced and became zero at the end of the 
study period. Only 15% patients were taking anti diabetic 
Mathew et al. 
Int J Pharm Pharm Sci, Vol 7, Issue 9, 206-209 
208 
medication at an average of 500 mg/day in the bariatric group at 
one year post surgically. D. E Mumme et al. reported that after 
surgery only 20% patients need antidiabetic medications [6, 11]. In 
our study similar result was observed. 
 
 
 Fig. 1: changes in excess body weight loss after surgery 
 
Here the average weight loss>20% at each follow up showed in the Y 
axis. The X axis showing follows up in months. 
 
HbA1c value 
The remission of diabetes, (HbA1c less than 6% without active 
pharmacological therapy) was achieved in more than 85% patients 
of bariatric group at the end of study. In the conventional group only 
5% achieved 6.5% HbA1c level with antidiabetic medication. Two 
multi-centre study conducted by Daniel E, Mumme, Michal 
Mathiason [6] reported 89% remission of diabetes after bariatric 
metabolic surgery. In our study also more than 80% bariatric 
patients achieved remission at one year. The result of our study is 
comparable with above study. Complete remission means 
discontinuation of all diabetes related medication and HbA1c less 
than 6%. Elevated HbA1c is an indicator, widely accepted for 
diabetes measurement, every 1 % decrease in HbA1c the risk of 
diabetic complication decreases by 37% [9]. Bariatric surgery can 
result in diabetes remission. Buchwald et al. conducted a study for 
obesity and related complications reported that after bariatric 
surgery significant and consistent reduction HbA1c value was 
observed relative to the baseline value [7]. Fig. 2 shows the 
comparison of HbA1c at base line and after intervention in both 
groups. In conventional group mean HbA1c is 7.5% where as in 
bariatric group it is less than 6%.  
 
 
Fig. 2: Changes in mean value of glycosylated haemoglobin. 
 
Table 4: Anova for conventional group 
Source ss df ms f p 
Total 5184557.93 15    
Follow ups 36086.47 3 18043.24 1.095 >0.05 
Error 197794.02 12 16482.84   
ss-sum squares, df-degrees of freedom, ms-mean square*p value<.05 (significant). 
 
Table 4 shows the two factor anova for parameters and follow ups of 
conventional group. There is no significant difference between three 
follow ups because p value is more than (0.05). The parameters 
tested are BMI, excess weight loss and Glycosylated haemoglobin 
and medication use. 
Table 5 shows the two factor anova for parameters and follow ups 
under the surgery group. There is significant difference between 
baseline and follow ups (P<0.05). The three followed parameters 
BMI, Excess weight loss and Glycosylated haemoglobin were found 
to be statistically significant for surgical group. 
 
Table 5: Anova for bariatric group 
Source ss df ms f p 
Total 3126088.73 24    
Parameters 3000438.82 3 500073.14 89.533 <0.001 
Follow ups 25113.76 3 8371.25 1.499 <0.05 
Error 100536.15 18 5585.34   
ss-sumsquares of mean, df-degrees of freedom, ms-mean square*p value<.05 (significant). 
 
CONCLUSION 
Compared to conventional therapy bariatric surgery markedly 
improves diabetes and results in discontinuation or marked 
reduction of anti-diabetic medications in majority of patients 
treated, so bariatric surgery seems to be a better option for the 
obese diabetic patients. 
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